Trial Profile
Study of Apatinib Combined With TACE in Advance Hepatocellular Carcinoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 15 Jan 2018 New trial record